Sepsis and lipopolysaccharide (LPS) trigger the systemic release of both cytokines and catecholamines. Cytokines are known to be capable of eliciting a stress hormone response in vivo. The present study sought insight into the effect of noradrenaline on LPS-induced release of tumor necrosis factor alpha (TNF) and interleukin 6 (IL-6) in human whole blood. Whole blood was incubated with LPS for 4 h at 37°C in the presence and absence of noradrenaline and/or specific ox and I( antagonists and agonists. Noradrenaline caused a dose-dependent inhibition of LPS-induced TNF and IL-6 production. This effect could be completely prevented by addition of the specific 01 antagonist metoprolol, while it was not affected by the a antagonist phentolamine.
The lipopolysaccharide (LPS) component of the outer membrane of gram-negative bacteria is considered responsible for the pathological sequelae of gram-negative sepsis (10) . LPS triggers the production of cytokines, which in turn mediate most of the biological effects of LPS. Ample evidence that tumor necrosis factor alpha (TNF) is the first cytokine in a cascade of these proteins that is induced by LPS exists (6) . The essential role of TNF in the toxicity evoked by bacteremia has been carefully documented in animal studies showing that neutralization of TNF activity prevents mortality in otherwise lethal sepsis (25) . Interleukin 6 (IL-6) release follows shortly after the appearance of TNF in experimental endotoxemia and sepsis (7, 27) and is likely to be the major stimulus for acute-phase protein synthesis in systemic infection (16) .
In sepsis, high concentrations of TNF and IL-6 in serum are paralleled by markedly elevated levels of stress hormones in the circulation (8) (9) (10) (11) . Reciprocal interactions between cytokines and the endocrine system have been documented, i.e., cytokines can induce a stress hormone response when they are given systemically to various species, including humans (22, 26) , and stress hormones can affect the production of cytokines (2, 20, 21) . Mononuclear cells express both cx-and ,B-adrenergic receptors (14, 15, 20, 21, 29) . Adrenaline has been reported to diminish TNF production by mononuclear cells and human whole blood stimulated with LPS via an effect on ,B-adrenergic receptors (20) . Noradrenaline, however, has been demonstrated to augment LPS-induced TNF production by murine macrophages via stimulation of cx-adrenergic receptors (21) .
In the present study, we sought further insight into the effect of noradrenaline on the production of TNF and IL-6 elicited by LPS, as well as into the mechanisms that contribute to this effect. For this purpose, we used the previously validated system of endotoxin-stimulated cytokine production in human whole blood, which has been introduced as an ex vivo model to study cytokine synthesis in inflammatory conditions in which many of the physiologically present cellular interactions remain intact (3, 4) . Cytokine assays. Plasma TNF and IL-6 concentrations were measured with previously described enzyme-linked immunosorbent assays (5, 13) .
MATERIALS AND METHODS

Materials
Statistical analysis. All results are given as the mean ± the standard error of the mean (SEM). The TNF and IL-6 levels of various treatment groups were compared by using the Wilcoxon test for matched samples. Statistical significance was set at P < 0.05.
RESULTS
Effect of noradrenaline on LPS-induced TNF and IL-6 production. Incubation of whole blood for 4 h at 37°C in the absence of LPS did not result in detectable levels of TNF or IL-6. In addition, noradrenaline did not induce cytokine production in the absence of LPS (data not shown). LPS at concentrations of 1 and 10 ng/ml induced both TNF and IL-6 production in the whole-blood samples of all eight subjects tested in these experiments (Fig. 2) . Noradrenaline caused a dose-dependent inhibition of LPS-induced TNF and IL-6 release (Fig. 2 ). After incubation with 1 ng of LPS per ml, this inhibition was significant at a noradrenaline concentration of 1 ng/ml, whereas after incubation with 10 ng of LPS per ml, higher noradrenaline concentrations (10 ng/ml) were needed to inhibit cytokine production. Maximal inhibition was seen with the highest noradrenaline concentration (100 ng/ml), which reduced TNF levels to 8.3% ± 8.3% and 32.7% ± 8.8% of those found after incubation with LPS (1 and 10 ng/ml, respectively) alone and IL-6 concentrations to 49.8% ± 4.8% and 78.0% ± 8.0%.
Effect of a-and I-adrenergic antagonists on noradrenalineinduced inhibition of TNF and IL-6 production. To assess whether the inhibition of cytokine production by noradrenaline was mediated by an effect on ot-or 3-adrenergic receptors, whole blood from six subjects was incubated for 4 h at 37°C with LPS (10 ng/ml) and noradrenaline (10-9 to 10-6 M), with and without the specific ot antagonist phentolamine (10-5 M) and/or the specific f3 antagonist metoprolol (10-5 M) (28) (Fig. 3) . In the absence of noradrenaline, neither phentolamine nor metoprolol affected LPS-induced TNF and IL-6 production. In accordance with the experiments described above, noradrenaline caused a dose-dependent inhibition of LPS-induced TNF and IL-6 release. Phentolamine did not affect this inhibitory effect of noradrenaline. In contrast, metoprolol completely prevented it, i.e., TNF and IL-6 levels after incubation with LPS in the presence of noradrenaline and metoprolol were similar to those after incubation with LPS alone (P > 0.2 for the difference between LPS and noradren- aline plus metoprolol versus LPS alone for both TNF and IL-6 at all noradrenaline concentrations tested). The addition of metoprolol together with phentolamine (both 10-5 M) to whole blood incubated with LPS and noradrenaline resulted in TNF and IL-6 concentrations similar to those found after the addition of metoprolol alone (data not shown). Hence, these results suggested that noradrenaline inhibited LPS-induced cytokine production exclusively by an effect on the 31-adrenergic receptor.
Effect of specific a or specific 1 agonist on LPS-induced TNF and IL-6 production. To gain further evidence that the inhibition of cytokine production by noradrenaline was achieved by P-adrenergic stimulation, whole blood from six subjects was incubated for 4 h at 37°C with LPS (10 ng/ml) in the presence and absence of the specific ot-adrenergic agonist phenylephrine (10-10 to 10-6 M) or the specific 1 and 32 agonist isoprenaline (10`0 to 10-6 M) (28) (Fig. 4) . Phe- nylephrine did not affect LPS-induced TNF or IL-6 release. Isoprenaline, however, caused a dose-dependent reduction in LPS-induced TNF and IL-6 production, an effect that was significant at concentrations of 10-8 M and higher. At a concentration of 10-6 M, isoprenaline reduced TNF levels to 17.9% ± 4.1% and IL-6 levels to 61.8% ± 8.1% of those observed after incubation with LPS alone. induced TNF and IL-6 production is inhibition of LPS binding to or internalization into mononuclear cells. Therefore, we next investigated these issues by FACS analysis. Neither noradrenaline, isoprenaline, nor phenylephrine (each at a concentration of 10-' M) affected LPS-FITC binding to and internalization into mononuclear cells (Fig. 5) . Furthermore, noradrenaline did not alter the expression of CD14, the main receptor for LPS on mononuclear cells (20) (Fig. 6 ).
DISCUSSION
It has been widely recognized that LPS and cytokines can elicit the release of catecholamines in vivo (18, 22, 26) . More recent studies indicate that catecholamines may have a bimodal effect on LPS-induced TNF production, the eventual result depending on whether the cx-or 1-adrenergic receptor is preferentially stimulated (20, 21) . Knowledge of the effect of Thereafter, erythrocytes were lysed, leukocytes were washed, and anti-CD14-PE (10 ,ug/ml) was added. Mononuclear cells were gated, and expression of CD14 was measured by FACS analysis. x axis, fluorescence intensity; y axis, number of cells.
catecholamines on cytokine production in sepsis is important not only for the unraveling of feedback loops between these two mediators systems but also because of the fact that catecholamines are frequently administered to septic shock patients as vasoactive agents. This study aimed to assess the effect of noradrenaline on LPS-induced TNF and IL-6 production in human whole blood, an ex vivo system that has been shown to be a suitable model to study cytokine synthesis in sepsis (3, 4) . The use of whole blood eliminates artifacts that may be associated with the isolation of monocytes, such as adherence-induced expression of TNF (12) . Additionally, by using whole blood the effect of a hormone on the release of cytokines evoked by LPS can be investigated under conditions with a physiological endocrine background, which is likely to be of more relevance for the in vivo situation. Our results demonstrate that noradrenaline causes a dose-dependent inhibition of LPS-induced release of TNF and IL-6 and that this effect is mediated by P,-adrenergic receptors.
Mononuclear cells, which represent major producers of TNF and IL-6, express both cx-and ,B-adrenergic receptors on their surfaces (14, 15, 20, 21, 29) . Stimulation of ax-adrenergic receptors may result in an enhancement of immune cell responsiveness and augmentation of LPS-induced TNF production, whereas ,3-receptor stimulation may decrease immune cell activity and reduce LPS-induced TNF synthesis (15, 20, 21) . Noradrenaline binds to ox receptors and the PI receptor (28) . Recently, noradrenaline, at concentrations between 10-9 and 10-x M, has been reported to increase production of TNF by murine macrophages incubated with LPS for 4 h (i.e., similar to the incubation period used in our study), an effect that likely was solely mediated by o2 receptors (21) . At a concentration of 10" M, the potentiating effect of noradrenaline was less pronounced; the effect of higher concentrations, which may have revealed inhibition of LPS-induced TNF production by noradrenaline, was not reported (21) . In the present study, downregulation of LPS-induced TNF production was not observed until a noradrenaline concentration between 10 x and 10 7 M, an effect that could be completely prevented by the addition of a specific 1, antagonist and mimicked by a specific agonist. However, in contrast to the findings of the study cited immediately above (21), the stimulatory effect of noradrenaline was not observed at any concentration (lowest concentration tested, 10-"' M; data not shown). The reason for this apparent discrepancy remains to be established but may be related to interspecies differences and/or differences in experimental systems (i.e., isolated cells versus whole blood). Phenylephrine, the ax-adrenergic agonist used in the present study, has a higher affinity for cx, than eX2 receptors (28) . Theoretically, cx1-adrenergic stimulation may enhance TNF production by activation of protein kinase C (1, 17) . Our results demonstrate that stimulation of cx,-adrenergic receptors, in either the presence or absence of LPS, does not affect cytokine production in human whole blood. Furthermore, it is unlikely that cx-adrenergic stimulation enhances LPS-induced TNF production in human whole blood, considering the fact that a blockade of 1, receptors, allowing noradrenaline to bind only to ox, and cxo receptors, was not associated with an increase in TNF release elicited by LPS.
One mechanism by which ,-adrenergic agonists may inhibit TNF production is the well-documented capability of these agents to stimulate adenylate cyclase activity and to increase cyclic AMP (cAMP) synthesis (14, 20, 29) , since elevated levels of cAMP have been shown to suppress LPS-induced transcriptional activation of the TNF gene (23 magnitude than the inhibition of TNF release. It is unlikely that increasing cAMP levels contribute to the observed inhibition of IL-6 production, since cAMP-increasing agents have been reported to induce IL-6 gene expression and production in various cell types (19, 30) . In addition, it is unlikely that the reduction in IL-6 release was secondary to the inhibition of TNF production, since complete neutralization of TNF activity by the addition of an anti-TNF antibody did not reduce LPS-stimulated IL-6 release in human whole blood in a previous study (3) . Therefore, we addressed another mechanism by which noradrenaline may inhibit IL-6 (and TNF) production, i.e., the binding of LPS to mononuclear cells. It appeared that neither noradrenaline, isoprenaline, nor phenylephrine affected LPS-FITC binding to and internalization into mononuclear cells. In accordance, noradrenaline did not influence the expression of the main LPS receptor CD14 on mononuclear cells, although this does not preclude an effect of noradrenaline on the expression of other LPS receptors (24) .
Thus, other mechanisms must be involved.
In acutely septic patients, TNF and IL-6 are among the major cytokines found in the circulation. Our study demonstrates that noradrenaline attenuates LPS-induced release of TNF and IL-6 in human whole blood via stimulation of 3l-adrenergic receptors. These results exemplify the tight interaction between the cytokine network and the endocrine system and suggest that, in acute sepsis, noradrenaline (released at least partly by the action of TNF and IL-6) inhibits the ongoing production of these mediators as part of a negative feedback mechanism.
